Results 21 to 30 of about 277,103 (274)

Surrogate Endpoints in Health Technology Assessment [PDF]

open access: yes, 2020
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencies are increasingly faced with reliance on evidence from surrogate endpoints, leading to increased decision uncertainty.
Antal Zemplenyi   +41 more
core   +3 more sources

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers [PDF]

open access: yesAlzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Anthony Muchai Manyara   +2 more
doaj   +2 more sources

Biomarkers and surrogate endpoints [PDF]

open access: yesBritish Journal of Clinical Pharmacology, 2005
When David Beckham leaves the field towards the end of a match, the man who replaces him is a surrogate. and although I suspect that many footballers, if asked, would say that Surrogate is a town in Yorkshire, the word actually comes from the Latin word subrogare, to substitute.
openaire   +3 more sources

A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint

open access: yesPilot and Feasibility Studies, 2018
Background It has been argued that true endpoints (or ‘hard’ endpoints) for clinical trials, which are meaningful to clinicians, researchers and patients alike, are limited to those that measure health status, survival and cost.
M. J. Campbell   +2 more
doaj   +1 more source

Surrogate Endpoints for Late Kidney Transplantation Failure. [PDF]

open access: yesTranspl Int, 2022
In kidney transplant recipients, late graft failure is often multifactorial. In addition, primary endpoints in kidney transplantation studies seek to demonstrate the short-term efficacy and safety of clinical interventions.
Naesens M   +12 more
europepmc   +4 more sources

A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints [PDF]

open access: yes, 2015
In an adaptive seamless phase II/III clinical trial interim analysis data are used for treatment selection, enabling resources to be focussed on comparison of more effective treatment(s) with a control.
Friede, Tim   +6 more
core   +1 more source

Clinician Attitudes Toward Surrogate Endpoints

open access: yes
This project aims to conduct a realist review exploring clinician attitudes toward the use of surrogate endpoints across various medical specialties. Surrogate endpoints, commonly used in clinical trials to expedite results, are often debated for their ...
Jennifer Hinkel
core   +8 more sources

A perfect correlate does not a surrogate make

open access: yesBMC Medical Research Methodology, 2003
Background There is common belief among some medical researchers that if a potential surrogate endpoint is highly correlated with a true endpoint, then a positive (or negative) difference in potential surrogate endpoints between randomization groups ...
Kramer Barnett S, Baker Stuart G
doaj   +1 more source

How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.

open access: yesPLoS ONE, 2020
BACKGROUND AND OBJECTIVE:The use of valid surrogate endpoints can accelerate the development of phase III trials. Numerous validation methods have been proposed with the most popular used in a context of meta-analyses, based on a two-step analysis ...
Casimir Ledoux Sofeu, Virginie Rondeau
doaj   +1 more source

Home - About - Disclaimer - Privacy